Post-infarction remodeling, transverse aortic constriction as well as pro-hypertrophic agents such as angiotensin II, phenylephrine, endothelin-1, and isoproterenol are used to develop animal models of cardiac hypertrophy (Frey and Olson, 2003). The gene discussed is AGT; the disease is cardiac hypertrophy.